Summary

Patients with heart failure (HF) and previous myocardial infarctions (MIs) demonstrated favorable outcomes after treatment with JVS-100, a plasmid that encodes for stromal cell—derived factor-1. This article presents data from the Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure trial [STOP-HF; NCT01643590].